drugset / Trial / NCT00712829
Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents
RandomizedCrossoverSingle-blindDiagnostic
Summary
This is a single blinded, randomized, cross-over design. Up to 12 patients will be randomly administered a single 10.0 mCi dose of 123I-MIP-1072 or 123I-MIP-1095 (study drugs). The second (alternate) study drug will be administered approximately 14 days after the first. A final follow-up visit will occur approximately 2 weeks after the injection of the alternate study drug.
Timeline
- Start
- 2008-05
- Primary completion
- 2009-01
- Completion
- 2009-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 123-I-MIP-1072 | Small molecule | 370 mbq | Intravenous |
| Subject | 123-I-MIP-1095 | Small molecule | 370 mbq | Intravenous |